Tuesday November 23, 2021, 09:30 - 14:30
Wednesday November 24, 2021, 09:30 - 14:30

The Neuro Open Science in Action Symposium 2021 is the 3rd edition of the international symposium organized by The Neuro (Montreal Neurological Institute-Hospital) and the Tanenbaum Open Science Institute. This virtual two-day symposium provides a unique forum for global leaders in Open Science including researchers, patient advocates, policy-makers, funders, industry, philanthropic organizations, science communicators and other important stakeholders to discuss the latest and future developments in Open Science.

Openness is an essential component of the scientific process. One of the greatest promises of Open Science is in accelerating the development of diagnostic tools, treatments, and cures for diseases. This promise is what originally inspired The Neuro to commit to Open Science. Open Science will have this accelerative effect in all biomedical fields, however there are some areas in which it can have the greatest impact most quickly.

The reasons Open Science can have such a significant impact varies between fields. In some cases greater transparency, collaboration and sharing of scientific knowledge and materials is needed to tackle disease complexity. In others the difficulties arise out of conducting studies with widely dispersed patients. Yet others suffer from the lack of research funding. In many cases a key challenge is the lack of incentives for commercial development.

In this year’s symposium we want to highlight some of the biomedical fields in which Open Science can do the most good, and to feature speakers from diverse perspectives who are using the power of transparency and collaboration to move us closer to greater efficiency and a disease-free world.

As in previous editions, the symposium will highlight Open Science initiatives in neuroscience but for the first time, discussions will also focus on research areas where Open Science is equally important such as rare diseases, vaccines and antivirals and tropical diseases.


We suggest